Malignant Salivary Gland Neoplasm — Trials

Malignant Salivary Gland Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

225 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 63
Recruiting: 32
Ph III recruiting: 0
Growth YoY: —
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: 21.4%
Trials / 1,000 deaths: 56.6 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (23)

clinicaltrialsPublishedShowing 1–17 of 17 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07667400	Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer	not yet recruiting	Phase 1 / Phase 2	120	National Cancer Institute (NCI)NIH	1	Sep 28, 2026	clinicaltrials
NCT06462183	Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)	active not recruiting	Phase 1	105	Rgenta Therapeutics IncINDUSTRY	2	Sep 17, 2026